TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers.

scientific article

TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1212/WNL.0B013E31820A0E3B
P932PMC publication ID3034409
P698PubMed publication ID21178100

P50authorThomas G BeachQ67218653
Bradley F BoeveQ67501037
Dennis W. DicksonQ30504740
Elizabeth FingerQ42734328
Roberta GhidoniQ43188784
Luisa BenussiQ43188790
Ronald C. PetersenQ56839853
Marsel MesulamQ56862907
Eileen H BigioQ57020324
Minerva M CarrasquilloQ59661913
Charles L WhiteQ60638965
David S KnopmanQ63967707
Zbigniew K WszolekQ64754704
Giuliano BinettiQ64856448
P2093author name stringT Hunter
S G Younkin
N Johnson
D H Geschwind
W W Seeley
A Kertesz
B L Miller
M Baker
R Rademakers
G Coppola
G Forloni
I R Mackenzie
J Gonzalez
R Caselli
R Crook
N R Graff-Radford
J Crook
R Uitti
N Finch
C Lippa
P Sengdy
A M Karydas
K J Hantanpaa
M Dejesus-Hernandez
N J Rutherford
P2860cites workGenetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's diseaseQ24610759
PLINK: a tool set for whole-genome association and population-based linkage analysesQ24677407
Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filamentsQ24684804
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21Q28253639
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17Q28253651
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17Q28274687
Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteriaQ29614410
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusionsQ30434949
Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful agingQ33947272
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's DiseaseQ33955976
Clinicopathological correlates in frontotemporal dementiaQ34345893
Prediction of pathology in primary progressive language and speech disorders.Q35014616
Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesisQ35203303
Clinical and pathological characterization of progressive aphasiaQ36351816
Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survivalQ36527176
The genetics of frontotemporal lobar degenerationQ36926070
The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developmentsQ36931728
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementiaQ36967985
Frontotemporal dementia: clinicopathological correlationsQ37069848
Loss of progranulin function in frontotemporal lobar degenerationQ37105126
Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family membersQ37148011
Gene expression study on peripheral blood identifies progranulin mutationsQ37411590
Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration.Q40051471
Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repairQ40677795
Tau is a candidate gene for chromosome 17 frontotemporal dementiaQ42456776
Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion.Q51973117
P433issue5
P407language of work or nameEnglishQ1860
P304page(s)467-474
P577publication date2010-12-22
P1433published inNeurologyQ1161692
P1476titleTMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers
P478volume76

Reverse relations

cites work (P2860)
Q64768946Q64768946
Q38841003"New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS).
Q47620193A Dementia-Associated Risk Variant near TMEM106B Alters Chromatin Architecture and Gene Expression.
Q53691504A Novel Loss-of-Function GRN Mutation p.(Tyr229*): Clinical and Neuropathological Features.
Q36775677Advances in understanding the molecular basis of frontotemporal dementia
Q35160833Allelic expression of deleterious protein-coding variants across human tissues
Q36121377Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program
Q34500097Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72
Q38206207C9ORF72 hexanucleotide repeats in behavioral and motor neuron disease: clinical heterogeneity and pathological diversity
Q29465782C9orf72 binds SMCR8, localizes to lysosomes, and regulates mTORC1 signaling
Q39165154C9orf72: At the intersection of lysosome cell biology and neurodegenerative disease
Q97535454CRISPR-based functional genomics for neurological disease
Q92173373Characterization of lysosomal proteins Progranulin and Prosaposin and their interactions in Alzheimer's disease and aged brains: increased levels correlate with neuropathology
Q39472371Circulating progranulin as a biomarker for neurodegenerative diseases
Q35545502Differential clinicopathologic and genetic features of late-onset amnestic dementias
Q48122054Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy
Q37609848Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency
Q37248850Epidemiology and genetics of frontotemporal dementia: a door-to-door survey in southern Italy.
Q35063181Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains
Q37485507Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain
Q38394075Frontotemporal Dementias
Q26768177Frontotemporal Lobar Degeneration and MicroRNAs
Q59800165Frontotemporal dementia causative CHMP2B impairs neuronal endolysosomal traffic-rescue by TMEM106B knockdown
Q36073666Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology
Q28081198Frontotemporal dementia: a bridge between dementia and neuromuscular disease
Q37928504Frontotemporal dementia: from Mendelian genetics towards genome wide association studies
Q35204586Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine
Q38040822Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management
Q38802501Gene regulation and genetics in neurochemistry, past to future.
Q89438455Genetic Modifiers in Neurodegeneration
Q38786774Genetics of FTLD: overview and what else we can expect from genetic studies
Q34248849Genetics of dementia
Q92477950Genome Wide Association Study and Next Generation Sequencing: A Glimmer of Light Toward New Possible Horizons in Frontotemporal Dementia Research
Q34658391Genome-wide association studies in neurology
Q28250864Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A
Q37882469Human genetics as a tool to identify progranulin regulators
Q90127184Impairment of Lysosome Function and Autophagy in Rare Neurodegenerative Diseases
Q41455989Intracellular Proteolysis of Progranulin Generates Stable, Lysosomal Granulins that Are Haploinsufficient in Patients with Frontotemporal Dementia Caused by GRN Mutations
Q55484201Longitudinal structural gray matter and white matter MRI changes in presymptomatic progranulin mutation carriers.
Q48187381Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice.
Q99420895Loss of TMEM106B potentiates lysosomal and FTLD-like pathology in progranulin-deficient mice
Q55209391Loss of Tmem106b is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity.
Q28585799Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B
Q36003800Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration
Q64106726Microglial Progranulin: Involvement in Alzheimer's Disease and Neurodegenerative Diseases
Q39035458Molecular Genetics of Neurodegenerative Dementias
Q26766487Molecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric Disorders
Q37235164Novel progranulin mutations with reduced serum-progranulin levels in frontotemporal lobar degeneration
Q92606686Omics in Neurodegenerative Disease: Hope or Hype?
Q50980787Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter Italian study.
Q55439517Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency.
Q26782984Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia
Q53820484Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study.
Q26863702Potential mechanisms of progranulin-deficient FTLD
Q37293615Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers.
Q37978700Progranulin axis and recent developments in frontotemporal lobar degeneration
Q47966141Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study
Q47623958Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease
Q36826623Progranulin: an emerging target for FTLD therapies
Q27024421Progranulin: at the interface of neurodegenerative and metabolic diseases
Q37485657Promoter DNA methylation regulates progranulin expression and is altered in FTLD.
Q92381285Putative risk alleles for LATE-NC with hippocampal sclerosis in population-representative autopsy cohorts
Q38015344Recent insights into the involvement of progranulin in frontotemporal dementia.
Q52347550Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer's Disease and Frontotemporal Dementia.
Q35883188Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin
Q93013749TDP-43 and Limbic-Predominant Age-Related TDP-43 Encephalopathy
Q34566756TDP-43 in aging and Alzheimer's disease - a review
Q64217982TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia
Q35512313TMEM106B a novel risk factor for frontotemporal lobar degeneration
Q44624389TMEM106B and APOE polymorphisms interact to confer risk for late-onset Alzheimer's disease in Han Chinese
Q42845421TMEM106B and frontotemporal lobar degeneration: can over-expression tell us how reductions are beneficial?
Q33746240TMEM106B expression is reduced in Alzheimer's disease brains
Q55455470TMEM106B haplotypes have distinct gene expression patterns in aged brain.
Q37730909TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions
Q37154601TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia
Q37621660TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia
Q36307120TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease
Q36247028TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways
Q42332631TMEM106B: a strong FTLD disease modifier
Q24314869The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes
Q42089594The Lysosomal Trafficking Transmembrane Protein 106B Is Linked to Cell Death
Q88571271The Post-GWAS Era: From Association to Function
Q35153681The TMEM106B locus and TDP-43 pathology in older persons without FTLD
Q38825197The clinical spectrum of sporadic and familial forms of frontotemporal dementia.
Q42962467The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function
Q56594618The lysosomal function of progranulin, a guardian against neurodegeneration
Q36485513The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum
Q37067641The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia
Q26998919Therapeutic and diagnostic challenges for frontotemporal dementia
Q38797600TiME for TMEM106B
Q34311246Transmembrane protein 106A is silenced by promoter region hypermethylation and suppresses gastric cancer growth by inducing apoptosis
Q38062966Treatment implications of C9ORF72.
Q42323240Unusually long duration and delayed penetrance in a family with FTD and mutation in MAPT (V337M).
Q38571992Update on Hippocampal Sclerosis
Q38932474What we know about TMEM106B in neurodegeneration
Q37187461Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease
Q91962076White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study
Q47707736miR-34b-5p inhibition attenuates lung inflammation and apoptosis in an LPS-induced acute lung injury mouse model by targeting progranulin.

Search more.